Abstract
We are glad to introduce several variants of pharmacological correction of ischemic hepatic injury by three different types of medicines—incretinomimetics, imidazoline receptor’s agonists and biguanides. The study was conducted at the center for preclinical studies, Belgorod National Research University.
The experiment was performed on both sex rats, divided into seven groups (n = 10): An intact group, pseudo-operated animals (autopsy of the abdominal wall without ligation of the liver vessels), ischemia/reperfusion group without drug correction, animals undergoing ischemia/liver reperfusion + metformin (50 mg/kg), animals undergoing ischemia/liver reperfusion + moxonidine (1 ?g/kg), animals undergoing ischemia/liver reperfusion + C7070 (10 mg/kg). For the evaluation, the coefficients calculated from the level of hepatic transaminases (ALT, AST), as well as morphometric ratios of the area
of necrosis and deep ischemia of the liver, were used for evaluation according to the histological examination.
The experiment was performed on 50 rats of both sexes, divided into the next groups (n = 10): An intact group; pseudo-operated animals (autopsy of the abdominal wall without ligation of the liver vessels), ischemia/reperfusion group without drug correction, animals undergoing ischemia/liver reperfusion + metformin (50 mg/kg), animals undergoing ischemia/liver reperfusion + moxonidine (1 ?g/kg), animals undergoing ischemia/liver reperfusion + C7070 (10 mg/kg), animals undergoing ischemia/liver reperfusion + vildagliptine (0.2 mg/kg), animals undergoing ischemia/liver reperfusion + exenatide (10 ?g/kg). For the evaluation, the coefficients calculated from the level of hepatic transaminases (ALT, AST), as well as morphometric ratios of the area of necrosis and deep ischemia of the liver, were used for the evaluation according to the histological
examination.
Conclusion The imidazoline receptor agonists significantly and significantly reduce the functional and morphological manifestations of liver ischemia/reperfusion.
Keywords
Full Text:
References
Kolmykov DI, Alehin SA. Ischemia/reperfusion effect on pancreatic volumetrical blood flow velocity. Res Result Pharmacol Clin Pharmacol. 2015;1:42–46.
Chigunadze AL, Artyushkova EB, Mishustin VN, Goryainova GN, Artyushkova EV. Experimental justification of new way of pharmacological correction for contact frostbite using DSLET opioid peptide and serotonin adipinate to enhance surgycal treatment. Res Result Pharmacol Clin Pharmacol. 2016;2:3–19.
Ragulina VA, Kostina DA, Dovgan AP, Burda YE, Nadezhdin SV. Nuclear factor kappa B as a potential target for pharmacological correction endothelium-associated pathology. Res Result Pharmacol Clin Pharmacol. 2017;3:114–124.
Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update, Ann Intern Med. 2002;137:25–33.
Chan CK, Head GA. Relative importance of central imidazoline receptors for the antihypertensive effects of moxonidine and rilmenidine. J Hypertens. 1996;14:855?864.
Amann K, Nichols C, Tornig J, Schwarz U, Zeier M, Mall G, Ritz E. Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant. 1996;11:1003?1011.
Bing C, King P, Pickavance L, et al. The effect of moxonidine on feeding and body fat in obese Zucker rats colon: role of hypothalamic NPY neurons. Br J Pharmacol. 1999;127:35?42.
Bauduceau B, Mayaudon H, Dupuy O. Rilmenidine in the
hypertensive type-2 diabetic: a controlled pilot study versus captopril. J Cardivasc Risk 2000;7:57?61.
Wang GW, Klein JB, Kang YJ. Metallothionein inhibits doxorubicin-induced mitochondrial cytochrome c release and caspase-3 activation in cardiomyocytes. J Pharmacol Exp Ther. 2001;298:461–468.
Molchanova OV, Pokrovskaya TG, Povetkin SV, Reznikov KM. Endothelioprotective property of the combination of the thioctic acid and rosuvastatin shown in the endothelial dysfunction models. Res Result Pharmacol Clin Pharmacol. 2016;2:9–15.
Ban K, Noyan-Ashraf MH, Hoefer J, Bolz, SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Int J Cardiol. 2008;118:2340–2350.
Read PA, Khan FZ, Dutka DP. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart. 2012;98:408–413.
Vlasov TD, Simanenkova AV, Dora SV, Shlyakhto EV. Mechanisms of neuroprotective action of incretin mimetics. Cardiology Diabetes. 2016;19:16–23.
Basalay M, Barsukevich V, Mastitskaya S, Mrochek A, Pernow J, Sjöquist PO, et al. Remote ischaemic pre- and delayed postconditioning – similar degree of cardioprotection but distinct mechanisms.
Exp Physiol. 2012;97:908–917.
Vávrová A, Popelová O, St?rba M, Jirkovský E, Hašková P, Mertlíková-Kaiserová H, et al. In vivo and in vitro assessment of the role of glutathione antioxidant system in anthracycline-induced cardiotoxicity. Arch Toxicol. 2011;85:525–535.
Ravassa S, Zudaire A, Díez J. GLP-1 and cardioprotection: from bench to bedside. Cardiovasc Res. 2012;94:316–323.
Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting betacells. J Biol Chem. 1993;268:19650–19655.
Thorens B, Porret A, Bühler L, Deng SP, Morel P, Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 2003;42:1678–1682.
Fuglesteg BN, Suleman N, Tiron C, Kanhema T, Lacerda L, Andreasen TV, et al. Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulintherapy at reperfusion. Basic Res Cardiol. 2008;103:444–453.
Lacerda L, Somers S, Opie LH, Lecour S. Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovasc Res. 2009;84:201–208.
Hausenloy DJ, Lecour S, Yellon DM. Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid Redox Signal. 2011;14:893–907.
Tamareille S, Mateus V, Ghaboura N, Jeanneteau J, Croué A, Henrion D, et al. RISK and SAFE signaling pathway interactions in remote limb ischemic preconditioning in combination with local ischemic postconditioning. Basic Res Cardiol. 2011;106:1329–1339.
Tarasova AP, Danilenko LM, Tatarenkova IA, Khavanskii AV, Timokhina AS, Dovgan AP. Evaluation of cardioprotective effects of the incritinmimetics exenatide and vildagliptin in the experiment. Res Result Pharmacol Clin Pharmacol. 2017;3:57–63.
Tarasova AP, Danilenko LM, Sernov LN. Effect of pharmacological preconditioning with incretinomimetics exenatide and vildagliptin on the survival of ischemic tissues. Res Result Pharmacol Clin Pharmacol. 2017;3:132–150.
Dovgan AP. Ligand of peripheral imidazoline receptors based on amides of heterocyclic acids C7070: effect on ishemized tissues. Res Result Pharmacol Clin Pharmacol. 2017;3:78–88.
Buzov AA, Kulikov AL, Avtina TV, Pokrovskii MV, Osipova OA. Development and validation of methods of quantitative determination of the new antidiabetic drug in the blood plasma of rats by high performance liquid chromatography with mass spectrometric detection. Res Result Pharmacol Clin Pharmacol. 2016;2:52–57.
Dovgan AP, Urojevskaya JS, Khavansky AV. Possible ways of pharmacological correction of ischemic damage to the liver with the agonist of peripheral imidazoline receptors C7070. Res Result Pharmacol Clin Pharmacol. 2017;3:3–8.
Refbacks
- There are currently no refbacks.
Copyright (c) 2018 Journal of Pharmaceutical and Biomedical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.